QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
Log in
NASDAQ:EQ

Equillium Competitors

$7.59
-0.27 (-3.44 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.31
Now: $7.59
$8.02
50-Day Range
$5.20
MA: $7.19
$10.50
52-Week Range
$2.20
Now: $7.59
$27.05
Volume271,230 shs
Average Volume646,100 shs
Market Capitalization$187.88 million
P/E RatioN/A
Dividend YieldN/A
Beta1.71

Competitors

Equillium (NASDAQ:EQ) Vs. GOSS, PRVB, OGI, ANAB, RIGL, and CALT

Should you be buying EQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Equillium, including Gossamer Bio (GOSS), Provention Bio (PRVB), OrganiGram (OGI), AnaptysBio (ANAB), Rigel Pharmaceuticals (RIGL), and Calliditas Therapeutics AB (publ) (CALT).

Equillium (NASDAQ:EQ) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Equillium and Gossamer Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Equillium00303.00
Gossamer Bio00503.00

Equillium presently has a consensus price target of $14.00, indicating a potential upside of 84.45%. Gossamer Bio has a consensus price target of $22.80, indicating a potential upside of 132.89%. Given Gossamer Bio's higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Equillium.

Profitability

This table compares Equillium and Gossamer Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EquilliumN/A-60.79%-47.03%
Gossamer BioN/A-64.34%-46.52%

Volatility and Risk

Equillium has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Earnings & Valuation

This table compares Equillium and Gossamer Bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EquilliumN/AN/A$-25,600,000.00($1.47)-5.16
Gossamer BioN/AN/A$-180,310,000.00($3.29)-2.98

Equillium is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

31.1% of Equillium shares are owned by institutional investors. Comparatively, 72.0% of Gossamer Bio shares are owned by institutional investors. 52.3% of Equillium shares are owned by company insiders. Comparatively, 23.3% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Equillium (NASDAQ:EQ) and Provention Bio (NASDAQ:PRVB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Equillium and Provention Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Equillium00303.00
Provention Bio00403.00

Equillium presently has a consensus price target of $14.00, indicating a potential upside of 84.45%. Provention Bio has a consensus price target of $30.75, indicating a potential upside of 139.67%. Given Provention Bio's higher probable upside, analysts plainly believe Provention Bio is more favorable than Equillium.

Profitability

This table compares Equillium and Provention Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EquilliumN/A-60.79%-47.03%
Provention BioN/A-67.66%-62.27%

Volatility and Risk

Equillium has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Provention Bio has a beta of 3.34, suggesting that its stock price is 234% more volatile than the S&P 500.

Earnings & Valuation

This table compares Equillium and Provention Bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EquilliumN/AN/A$-25,600,000.00($1.47)-5.16
Provention BioN/AN/A$-43,280,000.00($1.06)-12.10

Provention Bio is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

31.1% of Equillium shares are owned by institutional investors. Comparatively, 39.4% of Provention Bio shares are owned by institutional investors. 52.3% of Equillium shares are owned by company insiders. Comparatively, 14.4% of Provention Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Equillium (NASDAQ:EQ) and OrganiGram (NASDAQ:OGI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Equillium and OrganiGram, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Equillium00303.00
OrganiGram08402.33

Equillium presently has a consensus price target of $14.00, indicating a potential upside of 84.45%. OrganiGram has a consensus price target of $2.93, indicating a potential downside of 4.87%. Given Equillium's stronger consensus rating and higher probable upside, equities analysts plainly believe Equillium is more favorable than OrganiGram.

Profitability

This table compares Equillium and OrganiGram's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EquilliumN/A-60.79%-47.03%
OrganiGram-207.26%-10.00%-7.14%

Volatility and Risk

Equillium has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, OrganiGram has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Earnings & Valuation

This table compares Equillium and OrganiGram's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EquilliumN/AN/A$-25,600,000.00($1.47)-5.16
OrganiGram$64.61 million11.07$-101,290,000.00($0.08)-38.50

Equillium has higher earnings, but lower revenue than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

31.1% of Equillium shares are owned by institutional investors. Comparatively, 10.8% of OrganiGram shares are owned by institutional investors. 52.3% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Equillium beats OrganiGram on 7 of the 13 factors compared between the two stocks.

Equillium (NASDAQ:EQ) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

31.1% of Equillium shares are held by institutional investors. 52.3% of Equillium shares are held by insiders. Comparatively, 13.0% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Equillium has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Equillium and AnaptysBio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Equillium00303.00
AnaptysBio03302.50

Equillium presently has a consensus price target of $14.00, indicating a potential upside of 84.45%. AnaptysBio has a consensus price target of $26.4286, indicating a potential upside of 1.73%. Given Equillium's stronger consensus rating and higher probable upside, research analysts plainly believe Equillium is more favorable than AnaptysBio.

Profitability

This table compares Equillium and AnaptysBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EquilliumN/A-60.79%-47.03%
AnaptysBioN/A-19.09%-17.94%

Earnings and Valuation

This table compares Equillium and AnaptysBio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EquilliumN/AN/A$-25,600,000.00($1.47)-5.16
AnaptysBio$8 million88.81$-97,340,000.00($3.60)-7.22

Equillium has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Summary

Equillium beats AnaptysBio on 8 of the 11 factors compared between the two stocks.

Equillium (NASDAQ:EQ) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

31.1% of Equillium shares are held by institutional investors. Comparatively, 82.0% of Rigel Pharmaceuticals shares are held by institutional investors. 52.3% of Equillium shares are held by insiders. Comparatively, 4.7% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Equillium has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Equillium and Rigel Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Equillium00303.00
Rigel Pharmaceuticals01302.75

Equillium presently has a consensus price target of $14.00, indicating a potential upside of 84.45%. Rigel Pharmaceuticals has a consensus price target of $8.3333, indicating a potential upside of 101.29%. Given Rigel Pharmaceuticals' higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Equillium.

Profitability

This table compares Equillium and Rigel Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EquilliumN/A-60.79%-47.03%
Rigel Pharmaceuticals-26.25%-44.96%-20.08%

Earnings and Valuation

This table compares Equillium and Rigel Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EquilliumN/AN/A$-25,600,000.00($1.47)-5.16
Rigel Pharmaceuticals$59.29 million11.80$-66,890,000.00($0.40)-10.35

Equillium has higher earnings, but lower revenue than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Equillium (NASDAQ:EQ) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

31.1% of Equillium shares are held by institutional investors. Comparatively, 11.9% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 52.3% of Equillium shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Equillium and Calliditas Therapeutics AB (publ), as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Equillium00303.00
Calliditas Therapeutics AB (publ)00403.00

Equillium presently has a consensus price target of $14.00, indicating a potential upside of 84.45%. Calliditas Therapeutics AB (publ) has a consensus price target of $38.00, indicating a potential upside of 31.76%. Given Equillium's higher probable upside, research analysts plainly believe Equillium is more favorable than Calliditas Therapeutics AB (publ).

Profitability

This table compares Equillium and Calliditas Therapeutics AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EquilliumN/A-60.79%-47.03%
Calliditas Therapeutics AB (publ)N/A-26.80%-25.38%

Earnings and Valuation

This table compares Equillium and Calliditas Therapeutics AB (publ)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EquilliumN/AN/A$-25,600,000.00($1.47)-5.16
Calliditas Therapeutics AB (publ)$19.56 million35.34$-3,450,000.00($0.19)-151.79

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Equillium. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Summary

Calliditas Therapeutics AB (publ) beats Equillium on 6 of the 10 factors compared between the two stocks.


Equillium Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
GOSS
Gossamer Bio
1.7$9.79-5.9%$743.34 millionN/A-2.75News Coverage
PRVB
Provention Bio
1.4$12.83-14.2%$724.74 millionN/A-8.61Analyst Report
News Coverage
Gap Up
OrganiGram logo
OGI
OrganiGram
1.2$3.08-9.1%$715.40 million$64.61 million-4.53Analyst Report
Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.1$25.98-1.9%$710.50 million$8 million-9.59Upcoming Earnings
Insider Buying
News Coverage
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$4.14-5.6%$699.58 million$59.29 million-27.60Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
CALT
Calliditas Therapeutics AB (publ)
1.3$28.84-0.1%$691.27 million$19.56 million-20.75
AKUS
Akouos
1.7$19.95-6.9%$685.94 millionN/A0.00High Trading Volume
News Coverage
Gap Up
Trading Halted
KDNY
Chinook Therapeutics
1.6$16.26-1.4%$685.49 million$17.26 million-4.52News Coverage
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$35.08-4.6%$669.22 million$9.64 million-5.71News Coverage
Chimerix logo
CMRX
Chimerix
1.1$10.67-4.6%$668.31 million$12.52 million-18.72News Coverage
BCEL
Atreca
1.7$17.75-3.6%$651.55 millionN/A-6.29
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$13.65-4.2%$647.97 millionN/A-5.48
Merus logo
MRUS
Merus
1.6$20.50-1.4%$647.86 million$31.13 million-6.68
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$18.12-1.4%$634.33 million$6.83 million-18.68Upcoming Earnings
News Coverage
IVA
Inventiva
0.0$15.54-0.3%$596.63 millionN/A0.00News Coverage
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.5$45.78-0.2%$596.51 million$195.89 million130.80Upcoming Earnings
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$33.22-4.3%$596.03 million$12.69 million-15.97Analyst Report
APLT
Applied Therapeutics
1.8$22.93-3.4%$584.58 millionN/A-4.82Insider Buying
Gap Down
Ardelyx logo
ARDX
Ardelyx
1.9$6.47-5.6%$583.91 million$5.28 million-6.41
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$16.30-1.8%$583.77 millionN/A0.00
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$6.97-7.6%$575.55 million$56.50 million0.00
ALT
Altimmune
1.9$17.20-13.8%$568.82 million$5.80 million-8.64Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
Geron logo
GERN
Geron
1.4$1.81-4.4%$561.95 million$460,000.00-5.17Analyst Downgrade
Analyst Revision
XBiotech logo
XBIT
XBiotech
1.2$18.94-0.0%$554.20 millionN/A1.31News Coverage
Molecular Templates logo
MTEM
Molecular Templates
2.0$11.02-5.0%$550.60 million$22.27 million-5.40Analyst Upgrade
Insider Buying
RLMD
Relmada Therapeutics
1.1$33.84-1.6%$549.63 millionN/A-15.67
AC Immune logo
ACIU
AC Immune
1.3$7.66-4.6%$549.54 million$111.75 million-8.51
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$11.08-1.1%$546.41 million$72.96 million-3.59
ISEE
IVERIC bio
1.5$6.01-2.8%$538.30 millionN/A-4.77Upcoming Earnings
Unusual Options Activity
News Coverage
BCYC
Bicycle Therapeutics
1.3$24.94-2.0%$531.35 million$13.80 million-12.05
UROV
Urovant Sciences
0.7$16.18-0.0%$529.78 millionN/A-3.14
IDYA
IDEAYA Biosciences
1.3$18.18-7.4%$528.49 millionN/A-9.67
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.60-3.9%$525.32 million$109.33 million-2.65News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.94-4.4%$524.62 million$143.01 million-1.13Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
NLTX
Neoleukin Therapeutics
1.4$12.43-1.7%$521.25 million$25 million-19.12
AMYT
Amryt Pharma
1.4$14.41-2.2%$515.39 million$58.12 million-16.76News Coverage
BeyondSpring logo
BYSI
BeyondSpring
1.2$13.06-5.1%$511.20 millionN/A-6.40
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$6.88-3.1%$510.04 millionN/A-14.04Analyst Upgrade
Analyst Revision
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.6$3.47-23.3%$501.55 million$335 million-1.17News Coverage
Gap Up
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.35-7.8%$499.96 millionN/A-5.31Upcoming Earnings
High Trading Volume
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$18.38-4.4%$499.70 million$18.15 million-4.32
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$8.88-5.6%$499.03 million$1.98 million-5.35Upcoming Earnings
Analyst Upgrade
News Coverage
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.6$15.05-4.1%$495.48 million$1.19 million-6.27
ETNB
89bio
1.6$24.87-0.5%$494.39 millionN/A-4.92News Coverage
SIGA
SIGA Technologies
0.3$6.38-1.9%$493.81 million$26.74 million15.95Upcoming Earnings
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.3$8.46-2.2%$492.99 million$59.22 million42.30News Coverage
Gap Down
SPRB
Spruce Biosciences
1.5$21.21-1.2%$492.37 millionN/A0.00Upcoming Earnings
Homology Medicines logo
FIXX
Homology Medicines
1.7$10.84-3.5%$490.66 million$1.67 million-3.97
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$20.89-5.0%$488.26 millionN/A0.00
MIRM
Mirum Pharmaceuticals
1.9$18.72-2.0%$481.42 millionN/A-5.44Analyst Upgrade
This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.